{"category":{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-04T03:51:05.029Z","updated_at":"2026-09-04T03:51:05.029Z","example":false,"profile_url":"/industries/pharmaceuticals","is_stub":true,"member_count":5,"member_counts":{"accelerator":1,"company":4}},"members":[{"listing_type":"company","name":"Acta Pharmaceuticals","slug":"acta-pharmaceuticals","tagline":"Alzheimer's therapies for early intervention and prevention, led by gamma-secretase modulator research","description":"Acta Pharmaceuticals, Inc. is a Boston biotech translating Alzheimer's research pioneered by scientific founder Dr. Rudolph E. Tanzi into clinical candidates for early intervention and prevention. Its lead program, GSM-779690T, is an oral gamma-secretase modulator in a Phase 1 healthy-volunteer study. In October 2026 the company announced closing $24 million in seed financing to advance the pipeline, alongside a combination-therapies discovery effort based on Alzheimer's-in-a-Dish models.","url":"https://actapharmaceuticals.com/","is_stealth":false,"normalized_domain":"actapharmaceuticals.com","normalized_url_key":"actapharmaceuticals.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://actapharmaceuticals.com/wp-content/uploads/2026/10/ACTA-Logo-26-FIN.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/acta-pharmaceuticals","platform":"linkedin"},{"label":"Funding announcement","url":"https://www.biospace.com/press-releases/acta-pharmaceuticals-closes-24-million-in-seed-financing-for-alzheimers-disease-pipeline-targeting-early-intervention-and-prevention"},{"label":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT07690228"}],"entry_points":[{"kind":"homepage","url":"https://actapharmaceuticals.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://actapharmaceuticals.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Rudolph E. Tanzi","role":"Scientific Founder","person_slug":"rudolph-e-tanzi-08macy2crbbz6","bio":null,"location":null,"links":[]},{"name":"George Alex","role":"Co-founder and CEO","person_slug":"george-alex-3gf4y8gl8xgyq","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"4b04d244-23da-4884-9262-5e34accafa91"},"categories":["Biotech","Healthcare","Pharmaceuticals","Alzheimer's"],"stage":"seed","founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/acta-pharmaceuticals","contact_email":null,"added_at":"2026-10-16T04:26:23.693Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T04:26:23.693Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"alzheimers","name":"Alzheimer's","note":null,"profile_url":"/industries/alzheimers"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T04:26:23.693Z","updated_at":"2026-10-16T04:26:23.693Z"}},{"listing_type":"company","name":"NuSynth Technologies","slug":"nusynth-technologies","tagline":"AI-enabled process innovation for complex chemistry","description":"NuSynth Technologies is a Bengaluru-based, R&D-led process innovation platform for complex chemistry that redesigns synthesis routes from first principles to improve cost, yield, cycle time, safety and sustainability, starting with pharmaceutical and electronic chemicals. Every experiment feeds an AI engine that builds a proprietary knowledge base for molecule selection, experimentation and scale-up. It raised a ₹36.5 crore (about $4M) seed round co-led by Avaana Capital and Shastra VC in October 2026.","url":"https://www.nusynthtech.com/","is_stealth":false,"normalized_domain":"nusynthtech.com","normalized_url_key":"nusynthtech.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.nusynthtech.com/assets/logo.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/nusynth-technologies","platform":"linkedin"},{"label":"Business Standard: seed round","url":"https://www.business-standard.com/companies/start-ups/nusynth-technologies-raises-36-5-crore-in-seed-funding-led-by-two-vcs-126101301199_1.html"}],"entry_points":[{"kind":"homepage","url":"https://www.nusynthtech.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.nusynthtech.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.nusynthtech.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[],"media":{"logo_asset_id":"ff18443c-b4f4-4c0d-8f45-4474b348570f"},"categories":["Chemicals","AI","Deep Tech","Pharmaceuticals","Sustainability"],"stage":"seed","founded_year":null,"location":"Bengaluru, India","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/nusynth-technologies","contact_email":null,"added_at":"2026-10-14T04:26:56.133Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-14T04:26:56.133Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"chemicals","name":"Chemicals","note":null,"profile_url":"/industries/chemicals"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"},{"kind":"industry","slug":"sustainability","name":"Sustainability","note":null,"profile_url":"/industries/sustainability"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-14T04:26:56.133Z","updated_at":"2026-10-14T04:26:56.133Z"}},{"listing_type":"company","name":"TriGemX Bio","slug":"trigemx-bio","tagline":"Biotech developing oral therapies for migraine","description":"TriGemX Bio (formerly Kallyope) is a New York City biotechnology company developing medicines for migraine. Its late-stage pipeline is led by elismetrep (K-304), an investigational oral TRPM8 channel blocker for the acute treatment of migraine that has entered Phase 3 development according to company announcements.","url":"https://trigemxbio.com/","is_stealth":false,"normalized_domain":"trigemxbio.com","normalized_url_key":"trigemxbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://trigemxbio.com/wp-content/uploads/2026/09/trigemx-logo-no-bio-e1790183632898.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/trigemxbio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.trigemxbio.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.trigemxbio.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.trigemxbio.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[],"media":{"logo_asset_id":"343ecc2d-33a4-45a0-9bae-14e903cc033b"},"categories":["Biotech","Healthcare","Pharmaceuticals"],"stage":"series-b+","founded_year":null,"location":"New York, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/trigemxbio","contact_email":null,"added_at":"2026-10-01T20:19:19.191Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-01T20:19:19.191Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-01T20:19:19.191Z","updated_at":"2026-10-01T20:19:19.191Z"}},{"listing_type":"company","name":"Kasvu Therapeutics","slug":"kasvu-therapeutics","tagline":"Small-molecule TrkB neuroplastogens for mental health and neurodegeneration","description":"Kasvu Therapeutics develops selective small-molecule TrkB positive allosteric modulators designed to promote neuroplasticity without hallucinogenic 5-HT2A activity. Its lead candidate KTX-0141 is advancing through IND/CTA-enabling studies for major depressive disorder, with clinical development planned to begin in the second half of 2027. The company is based on research from the University of Helsinki.","url":"https://www.kasvutx.com/","is_stealth":false,"normalized_domain":"kasvutx.com","normalized_url_key":"kasvutx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static1.squarespace.com/static/6756a0cfdda2a10f08bded80/t/6790f3cea7c1b546dec74191/1737552846975/Kasvu+some.png?format=1500w","links":[],"entry_points":[{"kind":"homepage","url":"https://www.kasvutx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.kasvutx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8619a8bf-5dac-4acc-a7f2-63643cc00d80"},"categories":["BioTech","Healthcare","Neurotech","Pharmaceuticals"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-24T20:24:24.167Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-24T20:24:24.167Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"neurotech","name":"Neurotech","note":null,"profile_url":"/industries/neurotech"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-24T20:24:24.167Z","updated_at":"2026-09-24T20:24:24.167Z"}},{"listing_type":"accelerator","name":"Bayer Co.Lab","slug":"bayer-co-lab","tagline":"Bayer's global network of life science incubators providing early-stage biotech startups with lab space, expert mentorship, and access to Bayer's worldwide…","description":"Bayer Co.Lab is a global network of life science incubators with locations in Berlin, Cambridge (US), Kobe, and Shanghai, providing early-stage entrepreneurs with state-of-the-art facilities, expert mentorship, and connections to Bayer's global research networks with no strings attached. The Co.Lab Connect program offers region-specific programs in Basel and Seoul to bridge local startups to global markets, particularly the US ecosystem. In 2025, the program selected Rege Nephro (Japan) and NXI Therapeutics (Switzerland) as inaugural Co.Lab Connect recipients.","url":"https://colab.bayer.com/","is_stealth":false,"normalized_domain":"colab.bayer.com","normalized_url_key":"colab.bayer.com","parent_slug":null,"parent":null,"type_data":{"application_url":"https://colab.bayer.com/","application_status":"rolling","formats":["In person"],"focus_areas":["Biotech","Pharmaceuticals","Life Sciences","Digital Health"],"equity_terms":"no strings attached","cohort_frequency":"rolling","portfolio_url":"https://colab.bayer.com/"},"logo":null,"links":[{"label":"Apply","url":"https://colab.bayer.com/","platform":"apply"}],"entry_points":[{"kind":"homepage","url":"https://colab.bayer.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://colab.bayer.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Accelerator","Incubator","Corporate","Biotech","Life Sciences","Pharmaceuticals","Digital Health"],"stage":null,"founded_year":null,"location":"Multiple (Berlin, Germany; Cambridge, USA; Kobe, Japan; Shanghai, China)","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/bayer-co-lab/","contact_email":null,"added_at":"2026-09-04T03:51:05.029Z","added_via":"web","geo":{"keywords":["Accelerator","Startup accelerator","Biotech","Pharmaceuticals","Life Sciences","Digital Health"],"canonical_facts":["Run by Bayer","Equity terms: no strings attached","Cohorts: rolling"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-04T03:51:05.029Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"accelerator","name":"Accelerator","note":null,"profile_url":"/industries/accelerator"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"corporate","name":"Corporate","note":null,"profile_url":"/industries/corporate"},{"kind":"industry","slug":"digital-health","name":"Digital Health","note":null,"profile_url":"/industries/digital-health"},{"kind":"industry","slug":"incubator","name":"Incubator","note":null,"profile_url":"/industries/incubator"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"pharmaceuticals","name":"Pharmaceuticals","note":null,"profile_url":"/industries/pharmaceuticals"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-04T03:51:05.029Z","updated_at":"2026-09-04T03:51:05.029Z"}}],"total":5,"limit":50,"offset":0}